News

Pegylated version (pegfilgrastim) Neulasta® is the more commonly prescribed agent, with a significantly longer half-life than its predecessor and is the preferred in patients receiving cancer chemotherapy.

According to the authors of a paper published in Lancet Oncology, we may have gathered enough evidence to begin to consider altering how these agents are approved, to speed their path to approval.

A study from Norway on whether switching stable patients with rheumatoid arthritis (RA) treated with Remicade® to a biosimilar has revealed that outcomes were no different.

As a result of increasing competition, a smaller player (in the biosimilar field) is seeking to sell its nascent biosimilar business.

Insulin glargine biosimilars supposed to contribute 15% to total cost savings in overall biologic expenditures.

Survey shows education will be needed to convince physicians of the value of biosimilar agents.

Amgen will await the outcome of its patent litigation with AbbVie before launching Amjevita.